PPARG and osteoarthritis: Rosiglitazone, a widely used peroxisome proliferator-activated receptor-γ (PPAR-γ) activator, inhibited lipid peroxidation and ferroptosis in smooth muscle cells and lung epithelial cells by inhibiting ACSL4 activity.37,227,228 PPAR-γ agonists inhibit MMP1 expression through a transcriptional mechanism and may help reduce joint tissue destruction.229 Moreover, low doses of rosiglitazone were shown to enhance the expression of type II collagen and TGF-β.230 Hence, rosiglitazone may exert a potential therapeutic effect on osteoarthritis.